— Know what they know.
Not Investment Advice

MENS NASDAQ

Jyong Biotech Ltd. Ordinary Shares
1W: +7.4% 1M: -3.1% 3M: -0.9% YTD: -36.1% 1Y: -95.5%
$2.18
+0.15 (+7.39%)
 
Weekly Expected Move ±12.4%
$2 $2 $2 $2 $3
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 33 · $165.7M mcap · 28M float · 0.272% daily turnover · Short 53% of daily vol

Balance Sheet Trends

Total Assets
$6M -22.8% ▼
4Y CAGR: -16.1%
Total Liabilities
$43M +1.3% ▲
4Y CAGR: +7.6%
Shareholders Equity
-$37M -7.2% ▼
Cash & Investments
$98K -44.6% ▼
4Y CAGR: -61.0%
Total Debt
$18M +8.7% ▲
4Y CAGR: +7.5%
Net Debt
$18M +9.2% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$4M$551K$718K$177K$98K
Short-Term Investments$664K$2M$94K$0$0
Cash & ST Investments$4M$2M$812K$177K$98K
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$2M$263K$2M$2M$108K
Total Current Assets$6M$3M$2M$2M$206K
Property, Plant & Equip.$7M$7M$6M$4M$3M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$10K$8K$283K$3M$3M
Total Non-Current Assets$7M$7M$6M$6M$6M
Total Assets$13M$9M$9M$8M$6M
— Liabilities —
Accounts Payable$25K$46K$4K$2K$3K
Short-Term Debt$5M$5M$8M$8M$7M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$151K$23K$4M$5M$3M
Total Current Liabilities$6M$6M$13M$14M$12M
Long-Term Debt$8M$6M$6M$9M$11M
Other Non-Current Liab.$18M$20M$19M$19M$20M
Total Non-Current Liabilities$26M$26M$25M$28M$31M
Total Liabilities$32M$33M$38M$42M$43M
— Equity —
Common Stock$1K$1K$1K$1K$1K
Retained Earnings-$15M-$19M-$26M-$30M-$33M
Accumulated OCI$189K$266K$590K$548K$1M
Total Stockholders Equity-$19M-$23M-$30M-$34M-$37M
Total Liabilities & Equity$13M$9M$9M$8M$6M
— Key Metrics —
Total Debt$14M$12M$14M$17M$18M
Net Debt$10M$11M$14M$17M$18M
Total Investments$664K$2M$94K$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms